Supernus Pharmaceuticals, Inc.

SUPNNASDAQUSD
44.75 USD
0.05 (0.11%)AT CLOSE (11:59 AM EDT)
44.74
0.01 (0.02%)
POST MARKET (AS OF 07:59 PM EDT)
Post Market
AS OF 07:59 PM EDT
44.74
0.01 (0.02%)
🔴Market: CLOSED
Open?$45.05
High?$45.73
Low?$44.60
Prev. Close?$44.70
Volume?574.1K
Avg. Volume?726.1K
VWAP?$44.91
Rel. Volume?0.79x
Bid / Ask
Bid?$38.44 × 100
Ask?$50.97 × 100
Spread?$12.53
Midpoint?$44.71
Valuation & Ratios
Market Cap?2.6B
Shares Out?58.0M
Float?55.4M
Float %?95.4%
P/E Ratio?N/A
P/B Ratio?2.41
EPS?-$0.50
Dividend?0.00%
Ex-Dividend?N/A

Supernus Pharmaceuticals, Inc. (SUPN) is currently trading at $44.75. Our models show a "Strong Sell" technical signal alongside a "Neutral" fundamental rating. Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 2/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. Valuation metrics place SUPN at a fair price relative to peers.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
Employees
778
Market Cap
2.6B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2012-05-01
Address
9715 KEY WEST AVENUE
ROCKVILLE, MD 20850
Phone: 301-838-2500
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bearish(-3/3)
Medium-Term (Wave)? Bearish(-2/3)
Short-Term (Ripple)? Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
97
Momentum?
87
Short Sent.?
40
Piotroski F-Score?2/9Weak
Altman Z-Score?4.83Safe
Confidence?55%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?8.55%Elevated
Short Interest?4.7M
Days to Cover?5.3
Free Float55.4M
Avg Daily Volume894.4K
Settlement Date2026-05-15
Financial Health
Current Ratio?1.96Adequate
Quick Ratio?1.72Adequate
Cash Ratio?0.49Low
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A
P/B?
Peers
100
S&P
66
2.41CHEAP
P/S?
Peers
100
S&P
46
3.34FAIR
P/FCF?
Peers
100
S&P
26
31.6FAIR
EV/EBITDA?
Peers
100
S&P
3
61.3HIGH
EV/Sales?
Peers
100
S&P
59
3.11FAIR
Returns & Efficiency
ROE?
S&P
13
-2.7%WEAK
ROA?
S&P
3
-1.9%WEAK
Cash Flow & Enterprise
FCF?$82.2M
Enterprise Value?$2.4B
Fundamentals ratios updated end of day